Cargando…

Correction to “Febuxostat Prevents the Cytotoxicity of Propofol in Brain Endothelial Cells”

Detalles Bibliográficos
Autores principales:	Hao, Jianli, Zhang, Weiqing, Tong, Rui, Huang, Zeqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022202/ https://www.ncbi.nlm.nih.gov/pubmed/35465124 http://dx.doi.org/10.1021/acsomega.2c01716

Ejemplares similares

Febuxostat Prevents the Cytotoxicity of Propofol in Brain Endothelial Cells
por: Hao, Jianli, et al.
Publicado: (2021)

Bupivacaine modulates the apoptosis and ferroptosis in bladder cancer via phosphatidylinositol 3-kinase (PI3K)/AKT pathway
por: Hao, Jianli, et al.
Publicado: (2022)

Febuxostat methanol solvate
por: Jiang, Qi-Ying, et al.
Publicado: (2011)

Febuxostat ethanol monosolvate
por: Gelbrich, Thomas, et al.
Publicado: (2020)

Successful febuxostat desensitization in a patient with febuxostat hypersensitivity: A Malaysian experience
por: Sulaiman, Narisa, et al.
Publicado: (2017)

The Encapsulation of Febuxostat into Emulsomes Strongly Enhances the Cytotoxic Potential of the Drug on HCT 116 Colon Cancer Cells
por: Fahmy, Usama A., et al.
Publicado: (2020)

Febuxostat and the Black Box Blues
por: Abeles, Aryeh M., et al.
Publicado: (2019)

Effects of febuxostat on markers of endothelial dysfunction and renal progression in patients with chronic kidney disease
por: Nata, Naowanit, et al.
Publicado: (2023)

Hypouricemic effect and safety of febuxostat used for prevention of tumor lysis syndrome
por: Maie, Koichiro, et al.
Publicado: (2014)

Management of hyperuricemia in gout: focus on febuxostat
por: Reinders, Mattheus K, et al.
Publicado: (2010)

Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy
por: Kojima, Sunao, et al.
Publicado: (2019)

Febuxostat, a novel xanthine oxidoreductase inhibitor, improves hypertension and endothelial dysfunction in spontaneously hypertensive rats
por: Shirakura, Takashi, et al.
Publicado: (2016)

Efficacy and safety of febuxostat in elderly female patients
por: Mizuno, Tomohiro, et al.
Publicado: (2014)

Diabetes and gout: efficacy and safety of febuxostat and allopurinol
por: Becker, M A, et al.
Publicado: (2013)

Celebrating Versatility: Febuxostat’s Multifaceted Therapeutic Application
por: Kraev, Krasimir Iliev, et al.
Publicado: (2023)

Long-Term Effect of Febuxostat on Endothelial Function in Patients With Asymptomatic Hyperuricemia: A Sub-Analysis of the PRIZE Study
por: Maruhashi, Tatsuya, et al.
Publicado: (2022)

XOR inhibition with febuxostat accelerates pulmonary endothelial barrier recovery and improves survival in lipopolysaccharide‐induced murine sepsis
por: Damarla, Mahendra, et al.
Publicado: (2017)

Febuxostat in the management of hyperuricemia and chronic gout: a review
por: Hu, Miao, et al.
Publicado: (2008)

Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout
por: Gaffo, Angelo L, et al.
Publicado: (2010)

Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease
por: Akimoto, Tetsu, et al.
Publicado: (2014)

Febuxostat: A Novel Agent for Management of Hyperuricemia in Gout
por: Bisht, Manisha, et al.
Publicado: (2011)

ANCA-positive pauci-immune glomerulonephritis and febuxostat treatment
por: Izzedine, Hassane, et al.
Publicado: (2012)

Crystal structure of febuxostat–acetic acid (1/1)
por: Wu, Min, et al.
Publicado: (2015)

Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat
por: Jordan, Andreas, et al.
Publicado: (2018)

Pharmacokinetics and pharmacodynamics of febuxostat under fasting conditions in healthy individuals
por: ZHANG, MEI, et al.
Publicado: (2014)

Cytotoxicity of propofol in human induced pluripotent stem cell-derived cardiomyocytes
por: Kido, Koji, et al.
Publicado: (2017)

Comment on: Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
por: Deng, Jian‐Hao, et al.
Publicado: (2022)

Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
por: Gao, Linggen, et al.
Publicado: (2021)

Population pharmacokinetic modelling of febuxostat in healthy subjects and people with gout
por: Kamel, Bishoy, et al.
Publicado: (2022)

Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia
por: Beara-Lasic, Lada, et al.
Publicado: (2010)

Xanthine Oxidase Inhibition by Febuxostat Attenuates Experimental Atherosclerosis in Mice
por: Nomura, Johji, et al.
Publicado: (2014)

Febuxostat improves outcome in a rat model of cancer cachexia
por: Konishi, Masaaki, et al.
Publicado: (2015)

Switching from allopurinol to febuxostat: efficacy and tolerability in hemodialysis patients
por: Mitsuboshi, Satoru, et al.
Publicado: (2015)

Effects of febuxostat on platelet-derived microparticles and adiponectin in patients with hyperuricema
por: Nishizawa, Tohru, et al.
Publicado: (2015)

Evaluation of effect of allopurinol and febuxostat in behavioral model of depression in mice
por: Karve, Ashwini V., et al.
Publicado: (2013)

The potential renoprotection of xanthine oxidase inhibitors: Febuxostat versus allopurinol
por: Ryu, Dong-Ryeol
Publicado: (2017)

Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis
por: Cuenca, John A., et al.
Publicado: (2019)

Comparison of the Effects of Allopurinol and Febuxostat on the Values of Triglycerides in Hyperuricemic Patients
por: Ziga-Smajic, Nermina, et al.
Publicado: (2020)

Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat
por: Quintana, Michael J, et al.
Publicado: (2023)

Development and evaluation of febuxostat solid dispersion through screening method
por: Sohn, Jeong Sun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tu5jb3qgctc0rtq0ruadbjr4rf